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Abstract
Background: Renal vasculitis presents as rapidly progressive glomerulonephritis and comprises of a group of 
conditions characterised by acute kidney failure, haematuria and proteinuria. Treatment of these conditions involves 
the use of steroid and non-steroid agents with or without adjunctive plasma exchange. Although immunosuppression 
has been successful, many questions remain unanswered in terms of dose and duration of therapy, the use of plasma 
exchange and the role of new therapies. This systematic review was conducted to determine the benefits and harms of 
any intervention for the treatment of renal vasculitis in adults.
Methods: We searched the Cochrane Central Register of Controlled Trials, the Cochrane Renal Group Specialised 
Register, MEDLINE and EMBASE to June 2009. Randomised controlled trials investigating any intervention for the 
treatment of adults were included. Two authors independently assessed study quality and extracted data. Statistical 
analyses were performed using a random effects model and results expressed as risk ratio with 95% confidence 
intervals for dichotomous outcomes or mean difference for continuous outcomes.
Results: Twenty two studies (1674 patients) were included. Plasma exchange as adjunctive therapy significantly 
reduces the risk of end-stage kidney disease at 12 months (five studies: RR 0.47, CI 0.30 to 0.75). Four studies compared 
the use of pulse and continuous administration of cyclophosphamide. Remission rates were equivalent but pulse 
treatment causes an increased risk of relapse (4 studies: RR 1.79, CI 1.11 to 2.87) compared with continuous 
cyclophosphamide. Azathioprine has equivalent efficacy as a maintenance agent to cyclophosphamide with fewer 
episodes of leukopenia. Mycophenolate mofetil may be equivalent to cyclophosphamide as an induction agent but 
resulted in a higher relapse rate when tested against Azathioprine in remission maintenance. Rituximab is an effective 
remission induction agent. Methotrexate or Leflunomide are potential choices in remission maintenance therapy. Oral 
co-trimoxazole did not reduce relapses significantly in Wegener's granulomatosis.
Conclusions: Plasma exchange is effective in patients with severe ARF secondary to vasculitis. Pulse 
cyclophosphamide results in an increased risk of relapse when compared to continuous oral use but a reduced total 
dose. Whilst cyclophosphamide is standard induction treatment, rituximab and mycophenolate mofetil are also 
effective. Azathioprine, methotrexate and leflunomide are effective as maintenance therapy. Further studies are 
required to more clearly delineate the appropriate place of newer agents within an evidence-based therapeutic 
strategy.
Background
Renal vasculitis presents as rapidly progressive glomeru-
lonephritis (RPGN) which comprises a group of condi-
tions characterised by acute kidney failure (AKF),
haematuria and proteinuria. Histological examination of
t h e  ki d n ey  r ev ea l s  s ev e r e  i n fl a m m a t i o n  i n  t h e  f o rm  o f
crescent formation, glomerular necrosis and vasculitis of
small and medium sized vessels within the kidney. These
conditions include the anti-neutrophil cytoplasmic anti-
body (ANCA) associated vasculitides (AAV), anti-glom-
erular basement membrane (anti-GBM) disease and
idiopathic RPGN [1]. AAV are generally small vessel vasc-
ulitides and include Wegener's granulomatosis, micro-
scopic polyarteritis and renal limited vasculitis [2,3].
Evidence increasingly points to the pathogenicity of
ANCA [4]. Other conditions also cause vasculitis in the
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kidney such as Henoch Schonlein Purpura and cryoglob-
ulinaemia resulting in immune deposits visible on elec-
tron microscopic examination of renal tissue. The
treatment of Goodpasture's disease and other forms of
RPGN with granular immune deposits have an entirely
separate pathogenesis to the pauci-immune (no immune
deposits) forms of the disease and will not be addressed
in this review.
The treatment of systemic and renal vasculitis involves
the use of steroids in combination with other non-steroid
agents, most commonly, cyclophosphamide (CPA) [5,1]
to induce remission of disease. In the presence of kidney
failure, plasma exchange is often used as an adjunct to
pharmacological treatment [6-8]. Once remission is
achieved, treatment is scaled back to maintenance ther-
apy with lower doses of steroids and CPA is replaced by a
less potent immunosuppressive, such as azathioprine
(AZA). Co-trimoxazole has been used in Wegener's gran-
ulomatosis mainly to prevent the occurrence of pneumo-
cystis infection, upper respiratory tract infection and
subsequent relapse of disease. Various guidelines are
available which summarise available treatment options
and some of the evidence for their use[9-11]
These treatments are well established but many ques-
tions remain unanswered [12]. Optimal agent, dose,
duration, route and frequency of treatment are uncertain.
CPA can be given as a daily oral dose or as intermittent
oral or intravenous doses. Intravenous regimens tend to
give a lower total dose and have fewer side effects, but
may later give a higher rate of relapse [13]. Treatment
may include intravenous methylprednisolone or plasma
exchange but their place in therapy is debated [14,15].
Other therapies including Mycophenolate mofetil
(MMF), anti-TNF therapy, leflunomide, methotrexate,
anti-CD52 therapy, B cell depletion therapy and intrave-
nous immunoglobulin have been suggested [16-18] but
their place is not yet clear.
A previous version of the review has been published in
the Cochrane library[19]. This did not include the recent
data on the use of pulse cyclophosphamide[20], myco-
phenolate mofetil[21], leflunomide[22], methotrexate
[23], rituximab[24,25] and etanercept[26]. The most
notable of these is the data on pulse versus continuous
cyclophosphamide and its contribution to the current
debate on whether a reduction in total dose of cyclophos-
phamide will increase the rate of relapse. This question
cannot currently be answered by the randomised con-
trolled trials. This systematic review data is currently the
best available evidence to contribute to that debate.
Methods
Objectives
To evaluate the benefits and harms of any intervention
used for the treatment of renal vasculitis in adults.
Studies
All RCTs and quasi-RCTs looking at any intervention
used for the treatment of renal vasculitis in adults. Quasi-
RCTs were included in the protocol because we expected
few RCTs to be identified. Foreign language studies were
not excluded.
Participants
All adults suffering from an episode of AKF and/or pro-
teinuria and haematuria with a kidney biopsy showing
severe acute glomerulonephritis with crescents, glomeru-
lar necrosis or other histological evidence of vasculitis.
AKF was as defined by the included studies.
Outcome measures
Mortality, kidney function, need for renal replacement
therapy (RRT), number of patients relapsing, adverse
effects of each intervention.
Search methods
Relevant studies were obtained form the following
sources (see Appendix 1 for more detail):
1. The Cochrane Renal Group's specialised register 
and the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in The Cochrane Library, (Issue 1, 
2008).
2. MEDLINE (1966 to July 2009) using the optimally 
sensitive strategy developed for the Cochrane Collab-
oration for the identification of RCTs ([27])
3. EMBASE (1980 to July 2009) using a search strategy 
adapted from that developed for the Cochrane Col-
laboration for the identification of RCTs ([28]
4. Reference lists of nephrology textbooks, review 
articles and relevant studies.
Included and excluded studies
The review was undertaken by three authors (GW, NW,
JC). The titles and abstracts were screened independently
by GW and NW who independently assessed abstracts.
Disagreements were resolved in consultation with JC.
Study quality
The quality of studies to be included were assessed inde-
pendently by GW and NW without blinding to author-
ship or journal of publication using the check list
designed by the Cochrane Renal Group. Discrepancies
were resolved in discussion with JC. The quality items to
be assessed are allocation concealment, blinding, inten-
tion to treat analysis, and completeness of follow-up.
Blinding was assessed for investigators, participants, out-
come assessors and data analysis.
Statistical assessment
For dichotomous outcomes results were expressed as a
risk ratio (RR) with 95% confidence intervals (CI). DataWalters et al. BMC Nephrology 2010, 11:12
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were pooled using the random effects model but the fixed
effects model were also analysed to ensure robustness of
the model chosen and susceptibility to outliers. Where
continuous scales of measurement were used to assess
the effects of treatment, the mean difference (MD) was
used, or the standardised mean difference (SMD) if nec-
essary. Heterogeneity was analysed using χ2 test on N-1
degrees of freedom, with an α a of 0.05 used for statistical
significance and with the I2 test (Higgins 2003). I2 values
of 25%, 50% and 75% correspond to low, medium and
high levels of heterogeneity.
The summary measure data were translated into num-
ber needed to treat (NNT) and number needed to harm
(NNH) for the observed overall baseline risks. Adverse
effects were tabulated and assessed with descriptive tech-
niques.
Results
Description of studies
Twenty two studies (28 references, 1674 participants)
were identified as eligible for inclusion in this review. For
remission induction, six studies assess the use of plasma
exchange adjunctive therapy [7,29-33], four studies
address the use of pulse versus continuous cyclophosph-
amide treatment [20,34-36] and six further studies con-
sider other potential treatments including
rituximab[24,25], mycophenolate[21], lymphocytaphere-
sis[37], immunoadsorption [38] for remission induction
or intravenous immunoglobulin for refractory dis-
ease[16]. Maintenance treatment is considered by six
studies including comparisons of AZA after 3 months of
remission induction with continued CPA[39], AZA and
MMF[40], AZA and Methotrexate[23], Methotrexate and
Leflunomide[22], the use of co-trimoxazole[41] and etan-
ercept[26]. No quasi RCT studies were identified. The
demographics of the included patients are included in the
review in the Cochrane Library. The numbers of studies
identified by the search and subsequently excluded are
documented in the flow diagram in Figure 1
Plasma Exchange
Six studies addressed the adjunctive use of plasma
exchange with immunosuppression [29-33]. Inclusion
criteria are summarised in Table 1. The treatments tested
in each of these studies differed in terms of both the stan-
dard immunosuppression and the protocol for plasma
exchange (Table 2).
Plasma exchange significantly reduced the need for
dialysis at three months (1 study; RR 0.45 95% CI 0.24 to
0.84; P = 0.01; NNT = 5) and 12 months (5 studies; RR
0.47; 95% CI 0.30 to 0.75; P = 0.002; NNT = 5; I2 = 0%)
post-treatment (Figure 2). Jayne 2007 included patients
with SCr > 500 uM and showed a significant reduction in
the need for dialysis at three and 12 months. For all other
outcomes (death, SCr and side effects) there was no sig-
nificant difference between the treatment groups.
Pulse versus continuous cyclophosphamide
Four studies assessed pulse versus continuous adminis-
tration of CPA [20,34-36]. Systemic, rather than specifi-
cally renal, vasculitis was included. Raw data has been
obtained from Adu et al and those patients with polyar-
teritis nodosa have been excluded from this analysis.
Inclusion criteria are summarised in Table 3. The treat-
ment regimens in these studies also differed, as sum-
marised in Table 4.
Mortality was not significantly different between the
two groups. There was evidence of statistically significant
heterogeneity between the studies (Figure 3). There is a
trend towards an increase in the number of patients
requiring RRT with pulse CPA therapy, with twice as
many patients requiring dialysis on this treatment com-
pared to continuous treatment (Figure 4).
Remission rates were equivalent for the two interven-
tions (Figure 5; 3 studies; RR 0.99, 95% CI 0.96 to 1.03; P =
0.17; I2 = 34%). There was an increased risk of relapse
with pulse versus continuous therapy (Figure 6; 4 studies;
RR 1.79, 95% CI 1.11 to 2.87; P = 0.02; NNH = 5; I2 = 0%).
Leukopenia was less common with pulse treatment (4
studies; RR 0.53, 95% CI 0.36 to 0.77; P = 0.0009; NNH =
5; I2 = 0%), and nausea more common (2 studies; RR 2.51,
95% CI 1.07 to 5.89; P = 0.04 NNH = 7; I2 = 0%). Other
trends suggested less treatment failure but more serious
infections with continuous therapy but these were not
statistically significant. There was no significant differ-
ence in mortality and SCr.
Other remission induction studies
Inclusion and exclusion criteria, interventions and pri-
mary outcomes for these studies are detailed in tables 5
and 6.
Rituximab vs cyclophosphamide alone for remission 
induction
Two studies have been published in abstract form, the
RITUXVAS and RAVE studies[25,24]. In RITUXVAS, 44
patients with newly diagnosed AAV with renal involve-
ment were randomised 3:1 to receive rituximab or CPA.
Four doses of Rituximab were given with 2 doses of CPA
in the rituximab arm of the study. Primary end point was
sustained remission at 6 months. There was no difference
demonstrated for any outcome including remission and
adverse events.
The RAVE study distinguished itself by being a ran-
domised blinded study involving the use of placebo ritux-
imab infusions and CPA and AZA tablets. One hundred
and ninety seven patients with severe AAV were
recruited. Only 99 of these patients were classed as hav-Walters et al. BMC Nephrology 2010, 11:12
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Figure 1 Flow chart of study selection process.Walters et al. BMC Nephrology 2010, 11:12
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ing major renal involvement. Six month results are
reported in abstract form only. Primary outcome was dis-
ease remission in the absence of prednisolone therapy at
6 months. The results reported here are disease remission
at 6 months on Prednisolone 10 mg/d or less. As shown
in Figure 7 remission rates were similar between the two
groups.
Mycophenolate Mofetil for remission induction
The use of MMF for remission induction is compared
with CPA by Hu et al [21]. Thirty five patients with newly
diagnosed ANCA associated vasculitis and moderate
renal involvement were randomised to either 2 g/d MMF
or standard intravenous CPA monthly pulses for 6
months.
The primary outcome measure was remission rate at 6
months. MMF was found to be equivalent to CPA in this
limited population for remission at 6 months (1 study;
risk ratio 1.65; 95% confidence interval 0.94 to 2.90).
There were no data on relapse rate on either treatment.
Side effects appeared similar on both agents (risk ratio
0.65; 95% confidence interval 0.20 to 2.14)
Intravenous immunoglobulin for treatment of persistent 
disease
IVIg treatment for persistent disease has been studied by
a single RCT [16]. Thirty four patients with persistent
disease activity were randomised to IVIg 0.4 g/kg/d for 3
days or to identical placebo injections. The primary out-
come was a response to treatment defined as a 50%
reduction in BVAS (Birmingham Vasculitis Activity
Score).
The use of IVIg demonstrated a therapeutic response in
more patients at 3 months when compared with placebo.
(1 study; risk ratio 2.33; 95% confidence interval 1.18 to
4.61). Benefit was not demonstrated beyond 3 months.
There was no demonstrated difference in mortality or
rate of relapse.
Table 1: Inclusion and exclusion criteria for plasma exchange studies
Study Id Inclusion criteria Exclusion criteria
Cole 1992 RPGN of undefined aetiology (idiopathic or post 
infectious disease) with specific pathologic criteria.
Cellular crescents in < 50% non-obsolescent glomeruli.
Evidence of serious infection or active ulcer disease.
Adults (16-75 y), normal sized kidneys SCr > 170 μmol/L 
and/or increasing by 44 μmoles/l per wk.
No evidence of systemic disease or anti-glomerular 
basement membrane antibody-induced disease.
Renal biopsy within 5 days of trial entry
Jayne 2007 Biopsy-proven ANCA-associated necrotizing GN with 
acute kidney failure (SCr > 500 μmol/L)
Age <18 or > 80 years.
Inadequate contraception; pregnancy; previous 
malignancy; hepatitis B antigenaemia or hepatitis C 
antibody or HIV infection; other multi-system 
autoimmune disease; circulating anti-GBM antibody or 
linear staining of GBM on histology; life-threatening non-
renal manifestations of vasculitis.
Dialysis for > 2 weeks before entry; creatinine >200 uM 
more than 1 year before entry. > 2 weeks treatment with 
CPA or AZA; > 500 mg of IV methylprednisolone; plasma 
exchange within the preceding year; >3 months 
treatment with oral prednisolone; allergy to study 
medications.
Glockner 1988 RPGN with >70% crescents on renal biopsy.
CrCl < 50 ml/min.
Urine output > 200 ml/24 h.
Anti-GBM disease, life threatening conditions, 
contraindications to immunosuppression, previous 
treatment with AZA or CPA for >14 days.
Mauri 1985 Histologically proven crescentic GN and rapidly 
progressive renal impairment.
Less than 60% glomerular involvement, primary 
glomerulopathies, transplanted kidneys, SLE, HSP.
Pusey 1991 Focal necrotizing GN with crescents (Wegener's 
granulomatosis, systemic vasculitis, polyarteritis, 
idiopathic RPGN)
Anti-GBM disease, SLE, Henoch-Schonlein Purpura, 
chronic GN Previously treated with IV MP, oral CPA or PE
Rifle 1980 New onset RPGN with > 50% glomerular crescents. Goodpasture's syndrome; IgA nephropathies; SLE; 
systemic disease.Walters et al. BMC Nephrology 2010, 11:12
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Table 2: Interventions in the plasma exchange studies
Study ID Treatment Control Study outcomes
Cole 
1992
PE: at least 10 PE treatments 
within 16 days of trial entry.
One plasma volume with complete 
replacement using 5% albumin + 
crystalloid. 
Immunosuppression: as for 
control group
Immunosuppression
IV MP 10 mg/kg/d for 3 days followed 
by prednisone 1.4 mg/kg/d for next 4 days
and then tapered to 1 mg/kg/d over 2 
weeks 
0.35 mg/kg/d at 1 month and 0.25 mg/kg/d 
at 2 months.
AZA 1.5-3.0 mg/kg/d with dose 
adjustment 
as necessary to ensure neutrophil count of 
2.0 × 109/L or greater
1. renal pathology
2. Patients on dialysis at 
randomisation - dialysis at 1, 
3, 6, 12 months
3. Renal function in patients 
not on dialysis - 1, 3, 6, 12 months
4. Change in SCr
5. Adverse events (serious infections, 
gastrointestinal bleeding)
6. Mortality
Jayne 
2007
Seven PE of 60 ml/kg in first 2 
weeks after diagnosis
Immunosuppression as for control 
group
Three pulses of 1000 mg IV MP 
followed by oral CPA and a 
tapering regimen of prednisolone.
1. Mortality
2. Dialysis
3. Side effects
4. Serum creatinine 
at 12 months
Glockner
1988
Nine 50 ml/kg PE over 4 weeks 
replaced with 3-5% Albumin solution.
Immunosuppression as for control group
CPA 3 mg/kg/d plus AZA 1 mg/kg/d for 
1 week then AZA 2 mg/kg/d. 6-methyl 
prednisolone 1.5 mg/kg/d for 14 days 
reducing in 4 mg/d steps to 
maintenance 8 mg/d.
1. Mortality at 6 months
2. Dialysis at 6 months
3. SCr at 4 weeks, 8 weeks 
and 6 months
4. Adverse events including 
serious infections, GI 
haemorrhage and anaphylaxis
Mauri 
1985
PE alternate days for 6 treatments.
Exchanges of at least 3.5 L replaced 
with 3.5% Albumin and 2 units FFP.
Immunosuppression as for control group
CPA 2 mg/kg/d and Prednisolone 
1 mg/kg/d. Doses reduced to half 
after 8 weeks. Prednisolone dose 
tapered progressively. CPA dose 
reduced to 0.5 mg/kg/d after 2 
months then stopped after month 4.
1. Mortality
2. Dialysis post 
treatment, at 3 
months and 12 months 
after treatment
3. SCr after treatment 
and 6 months later
Pusey 
1991
PE: 5 × 4 L exchanges of 5% 
albumin (plasma protein fraction) 
within first week. Two units 
of fresh frozen plasma were given
at end of exchange. Total number 
of exchanges determined by clinical 
response. 
Immunosuppression as for control group
Induction therapy: 8 weeks of:
1. 60 mg/d prednisolone, reduce to 30 mg/d 
at week 3, taper slowly.
2. CPA 3 mg/kg/d or 2 mg/kg/d for those
over 55 years
3. AZA 1 mg/kg/d or no AZA for those 
over 55 years
Maintenance therapy: CPA stopped after 8 
weeks in those with remission and AZA 
increased to 2-3 mg/kg/d, together with 
tapering doses of prednisolone"
1. Improvement (fall in SCr > 25% 
or rise in CrCl > 25%; recovery 
of renal function in those initially 
on dialysis)
2. SCr
3. Dialysis
4. Death
5. Adverse event
Rifle 
1980
PE. Five sessions during 5 successive 
days, then 3 sessions/week until 
15 days after SCr reached a plateau. 
Treatment could not exceed 2 months. 
1.5 plasma volumes exchanged.
Immunosuppression as for control 
group
IV pulse MP (15 mg/kg/d for 3 days, 
tapered to 15 mg/d for 3 days, then 3 new 
pulses, then 15 mg/d for 7 weeks. 
CPA 2-3 mg/kg/d for 2 months. 
Calcium heparinate 9 days after renal 
biopsy for the duration of the study.
1. Dialysis 2, 6 12, 
24 months
2. CrCl at 2, 6 and 12 months.
3. Recovery (off dialysis) 
according to initial SCr level
4. Recovery (off dialysis) according 
to initial % of crescents
5. Death
6. Circulating immune complexes
7. Pathology changes
8. Adverse events (septicaemia)Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Immunoadsorption and Lymphocytapheresis
Immunoadsorption was compared to plasma exchange in
a single study [38]. 44 patients were randomised to
receive either immunoadsorption or plasma exchange. A
median of six sessions of each treatment were delivered.
Immunosuppression was otherwise the same in the
groups with standard CPA and prednisolone treatment.
Primary outcome was renal function and response to
treatment.
There was no detected difference in efficacy between
immunoadsorption and plasma exchange, as assessed by
mortality, the need for dialysis and SCr.
Lymphocytapheresis is compared to 3 days of iv meth-
ylprednisolone as adjunctive therapy by Furuta et al [37].
Twenty four patients were randomised with the primary
outcome being serum creatinine 4 weeks post treatment.
The use of lymphocytapheresis showed a highly signifi-
cant reduction in SCr at four weeks (1 study; MD -2.10,
95% CI -2.64 to -1.56). Other outcomes showed a ten-
dency to lower mortality (1 study; RR 0.40, 95% CI 0.10 to
1.67) and fewer patients on dialysis (1 study; RR 0.33, 95%
CI 0.04 to 2.77). However, the confidence intervals for
these are wide and clinical significance uncertain. No fur-
ther data has been published to support this study.
Maintenance Studies
Inclusion and exclusion criteria are detailed in Table 7
and the interventions in Table 8.
Azathioprine as maintenance therapy
The use of AZA to reduce exposure to CPA is assessed by
Jayne et al [39]. Patients were treated with standard
induction therapy of CPA 2 mg/kg/d and prednisolone 1
mg/kg/d. At remission, 155 patients were randomised to
either AZA 2 mg/kg/d and prednisolone 10 mg/d or con-
tinued CPA 1.5 mg/kg/d until 12 months, after which all
patients were treated with AZA 1.5 mg/kg/d. Primary
outcomes were relapse by 18 months and side effects of
treatment.
The introduction of AZA after remission did not alter
the rate of relapse at 18 months compared to the group
who remained on CPA (1 study; RR 1.13, 95% CI 0.51-
2.5). Leukopenia was significantly less likely on AZA (1
study; RR 0.65, 95% CI 0.42 to 0.99) though this was not
Figure 2 Forest plot showing the risk of requiring renal replacement therapy at 3, 6 or 12 months after induction treatment for vasculitis 
in patients treated with and without plasma exchange. At 3(1 study) and 12 months (5 studies) there is a significantly lower risk of requiring dialysis 
in patients treated with plasma exchange (PE).Walters et al. BMC Nephrology 2010, 11:12
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reflected in an increase in infective complications in
patients on CPA (1 study; RR 1.03, 95% CI 0.51 to 2.06).
MMF vs Azathioprine for maintenance treatment
One hundred and seventy four patients with newly diag-
nosed AAV were randomised after successful remission
induction to receive either MMF or AZA[40]. Primary
outcome was time to first relapse. Time to relapse was
shorter for the MMF group but this has not yet been
reported in detail. The abstract published states the haz-
ard ratio of relapse in the MMF group was 1.7 (95% CI
1.09-2.85; p = 0.03) suggesting that MMF treatment
results in a higher relapse rate in comparison with AZA.
Azathioprine vs Methotrexate for maintenance treatment
Pagnoux et al compared AZA and MTX for maintenance
treatment[23]. One hundred and twenty six patients
treated to remission with standard doses of intravenous
CPA and steroids were randomised to either AZA 2 mg/
kg/d or MTX 0.3 mg/kg/wk increasing by 2.5 mg/week to
a total of 25 mg/wk. Primary outcome was adverse reac-
tion causing death or leading to discontinuation of the
study drug. Secondary outcomes were any adverse event,
severe adverse event, relapse, relapse free survival, event
free survival and quality of life.
There was no difference between the treatments for
primary outcome (1 study; RR = 0.58 (95% CI 0.25-1.38).
Both treatments gave similar results for all the secondary
outcomes.
Leflunomide vs Methotrexate for maintenance treatment
Leflunomide was compared with methotrexate for remis-
sion maintenance [22]. Fifty four patients successfully
treated to remission with prednisolone and CPA, were
randomised to either leflunomide or methotrexate treat-
ment. The primary outcome was the number of relapses
after 24 months on treatment.
Leflunomide was shown to be superior to methotrexate
for relapse prevention in a time to event analysis in Met-
zler 2007. Our analysis suggests Leflunomide may be
superior but does not reach statistical significance (1
study; risk ratio 0.50; 95% confidence interval 0.22 to
1.11). Major relapses were also reduced (risk ratio 0.15;
95% confidence interval 0.02 to 1.17) and side effects sim-
ilar on both treatments (risk ratio 2.71; 95% confidence
interval 0.49 to 14.85). There were multiple methodologi-
cal difficulties with this study addressed in the discussion
section.
Etanercept as adjunctive therapy
The use of etanercept as adjunctive therapy in AAV was
investigated by the Wegener's Granulomatosis Etanercept
Trial Research Group [26]. One hundred and eighty
patients with new or established WG were randomised to
Table 3: Inclusion criteria for the pulse versus continuous CPA studies
Study ID Inclusion criteria Exclusion criteria
Adu 1997 Patients 15-70 y with new-onset systemic necrotizing 
vasculitis.
Wegener's granulomatosis, classical polyarteritis 
nodosa and microscopic polyarteritis diagnosed by 
histological or radiological evidence.
De Groot 2009a newly diagnosed Wegener's Granulomatosis, 
microscopic polyangiitis, or renal-limited microscopic 
polyangiitis renal involvement: at least one of: serum 
creatinine >150 umol/l and <500 μmol/l, biopsy 
evidence of necrotizing GN, erythrocyte casts, or 
haematuria and proteinuria, confirmatory histology or 
ANCA positivity
Other multi-system autoimmune disease; hepatitis B or 
C virus or HIV infection/Serum creatinine > 500 μmol/l; 
previous cancer; pregnancy; age under 18 yrs or older 
than 80 yrs.
Guillevin 1997 Age > 15 years
New diagnosis of systemic WG diagnosed clinically 
based on the presence of multi-organ involvement.
Mono-visceral involvement representing a potential risk 
or severe morbidity of fatality.
Histopathologic characterization of necrotizing 
granulomatosis vasculitis or evidence of either 
granulomatous inflammation and vasculitis or 
segmental necrotizing GN
NS
Haubitz 1998 New diagnoses of WG and MPA and renal involvement. 
Biopsy performed
Age < 18 y, pregnancy, HIV, malignancy, SCr > 200 μmol/
L more than 1 year before presentation, cytotoxic drug 
therapy for > 1 week before start of study, HD for > 10 
days before start of study.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Table 4: Interventions in the pulse versus continuous CPA studies
Study ID Treatment Control Study outcomes
Adu 1997 CPA 15 mg/kg and MP were given IV at 0, 2 
and 4 weeks. The same dose was then 
given 
as oral pulses over a 3-day period.
The interval between pulses was gradually 
increased.
initial treatment - 0.85 mg/kg 
prednisolone 
then tapering according to a predefined 
schedule for 72 weeks.
CPA 2 mg/kg/d given until a clinical 
decision 
that remission had been achieved at 
which 
point CPA was stopped and AZA 
commenced 
at 1.5 mg/kg/d
1. Complete and partial remission
2. Relapse
3. Adverse events
4. Treatment failure
5. Chronic dialysis
De Groot
2009a
3 iv pulses of CPA 15 mg/kg 2 weeks apart 
followed by 3 weekly pulses (15 mg/kg iv 
or 
5 mg/kg orally for 3 days) until remission 
then 
for another 3 months. 
Mac dose 1.2 G.
Reductions for age > 60 yrs and serum 
creatinine > 300 uM and for previous
low leukocyte nadir.
oral CPA 2 mg/kg/d to remission then 1.5 
mg/kg 
for further 3 months. Max oral dose 200 
mg. 
Reductions for age > 60 yrs and 
leukopenia
Both groups received Azathioprine 2 mg/
kg/d 
orally after induction therapy until month 
18.
Prednisolone 1 mg/kg orally tapered to 
12.5 mg/d 
at the end of month3 and 5 mg at end of 
study
1. Time to Remission
2. Change in renal function
3. Adverse events
4. Cumulative dose of CPA
Guillevin
1997
Initial regimen: IV MP 15 mg/kg/d for 3 
days. 
IV CPA 0.7 g/m2 day 4.
Oral prednisolone 1 mg/kg/d from day 4. 
IV pulse CPA: mean dose 0.7 g/m2 
adjusted for
count and renal function, administered 
every 
3 weeks until complete remission and 1 
year thereafter.
Then every 4 weeks for 4 months, every 5 
weeks for 4 months and every 6 weeks 
until 
discontinuation after 2 years if treatment.
Adjusted up or down based on neutrophil 
count.
Initial regimen: IV MP 15 mg/kg/d for 3 
days. 
IV CPA 0.7 g/m2 day 4. 
Oral prednisolone 1 mg/kg/d from day 4.
Oral CPA: 2 mg/kg/d on day 10 after initial 
CPA 
pulse, after neutrophil nadir had been 
reached.
1 year after complete remission, oral CPA 
was 
tapered by 25% every 4 months until 
discontinuation.
Dose adjusted up or down based on 
neutrophil count.
1. Treatment failure
2. Complete remission
3. Partial remission
4. Relapse
5. Death
6. Side effects
Haubitz
1998
Steroid regime: Days 1-3, 0.5 g IV MP. 
Day 4 1 mg/kg/d oral prednisolone. 
Tapered from day 15.
IV Pulse CPA - 0.75 g/m2 every 4th week. 
If CrCl < 30 ml/min, initial dosage was 0.5 
g/m2 
and increased to 0.75 g/m2 provided 
leukocyte 
counts remained > 3000/ml
Steroid regime: Days 1-3, 0.5 g IV MP. 
Day 4 1 mg/kg/d oral prednisolone. 
Tapered from day 15.  Oral daily CPA 
- 2 mg/kg/d. If CrCl < 30 ml/min, 
initial dosage started at 1.5 mg/kg/d and 
increase
to 2 mg/kg/d after 2 weeks provided 
leukocyte 
counts were > 3000/ml CPA dose reduced 
in steps 
of 0.5 mg/kg, unless leukocyte count was 
< 2500/ml then dose reduced by 50%, and 
if 
less than 1500/ml drug was withheld
until increased to 2500/ml
1. Complete remission
2. Partial remission
3. Relapse
4. Serious infectionWalters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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receive either etanercept 25 mg twice weekly by subcuta-
neous injection or placebo treatment. Immunosuppres-
sion with prednisolone and CPA for generalized or
methotrexate for limited disease was also given to both
groups. Primary outcome was sustained remission with a
BVAS/WG of 0 for at least 6 months.
Etanercept was not shown to be effective in remission
induction or relapse prevention. There was no difference
Figure 3 Forest plot showing the risk of death at 3, 6 and 12 months and 2 and 5 years and at final follow-up in patients treated with pulse 
or continuous cyclophosphamide. At no time point is there any significant difference between the treatment groups.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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in the induction of sustained remission (1 study; risk ratio
0.93; 95% confidence interval 0.77 to 1.11) or relapse rate
(1 study; risk ratio 0.93; 95% confidence interval 0.56 to
1.56). Moreover, the incidence of solid cancers detected
during the study was higher in the etanercept arm.
Co-trimoxazole for relapse prevention
Stegeman [41] studied the efficacy of co-trimoxazole in
preventing relapse of patients with ANCA associated vas-
culitis. Eighty patients with vasculitis and either RPGN
on biopsy or otherwise meeting the Chapel Hill Consen-
sus were randomised to co-trimoxazole 960 mg twice
daily or placebo. Primary outcomes were death, remis-
sion and relapse rate.
The reduction in the number of relapses in patients
treated with co-trimoxazole was a significant result on
the basis of life-table analysis, giving a reported RR of
relapse of 0.40 (95% CI 0.17 to 0.98). Our review, using a
fixed time analysis, suggests a smaller difference between
the groups with a higher probability of maintaining a
remission on antibiotics (1 study; RR 1.28, 95% CI 0.94 to
1.76) although this was not statistically significant (Figure
8).
Risk of bias in included studies
A summary of quality measures is shown in Table 9. Most
of the studies in this review were not blinded. Only three
reported blinding of patient, physicians and outcome
assessors. The majority of reports do not contain ade-
quate data to clearly indicate the risk of bias. Intention to
treat analysis was performed in 10 of 18 studies and fol-
low-up was good, ranging from 82 to 100%.
Figure 4 Forest plot showing the risk ratio of end stage renal failure in patients treated with either pulse or continuous cyclophosphamide 
therapy at 3, 6 or 12 months and at study end. Overall more patients require dialysis after treatment with pulse therapy but this does reach statis-
tical significance.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Discussion
Remission Induction
Plasma exchange as adjunctive therapy
This meta-analysis shows that plasma exchange confers a
significant benefit to many patients with RPGN by reduc-
ing the risk of end stage renal failure at 12 months from
diagnosis. The RR of 0.47 suggests that the number of
patients requiring dialysis may be halved by this interven-
tion. Previous studies have shown an effect in the most
severely ill patients. A subgroup analysis in Pusey 1991
showed a benefit for patients requiring dialysis at presen-
tation. More recently, Jayne 2007 has shown a benefit for
patients with SCr greater than 500 uM with ANCA asso-
c i a t e d  v a s c u l i t i s .  T h e  m a j o r i t y  o f  p a t i e n t s  i n c l u d e d  i n
these studies would meet the criteria for having severe
AKF (SCr > 500 uM or dialysis required at presentation).
Figure 5 Forest plot showing the risk ratio of achieving remission in patients treated with pulse or continuous cyclophosphamide at vari-
ous time points. There is no change in the rate of remission with pulse cyclophosphamide.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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It is therefore not clear whether plasma exchange has any
impact in patients whose kidney failure is not severe.
There was little statistical heterogeneity in all outcomes
of these studies with the single exception of SCr at 12
months.
Pulse versus continuous CPA
This analysis strongly suggests that, although pulse treat-
ment with cyclophosphamide is equivalent to continuous
treatment for remission induction, it results in a higher
rate of relapse subsequently. None of the studies in this
area have been adequately powered to answer the ques-
tion of relapse rate since this would require either much
larger studies or significantly longer follow-up. We are
therefore reliant on the results of meta-analysis to
attempt to provide an answer. This answer is less than
perfect since it is a meta-analysis of results at different
times post treatment across studies with significantly dif-
ferent protocols. In spite of that, there is no evidence of
heterogeneity in the outcome, suggesting that the final
result is likely to be valid. Though the rates of relapse with
pulse CPA treatment are perhaps discouraging, this does
not invalidate this mode of treatment. Pulse therapy still
delivers a significantly lower total dose of CPA. For those
patients who remain in remission, they have clearly bene-
fited in terms of risk of long term side effects.
There is a trend towards more patients requiring dialy-
sis with the use of pulse CPA therapy. This is currently
not statistically significant, but the fact remains that there
were twice as many patients requiring dialysis after pulse
therapy and that this effect is present in all studies. Fur-
ther studies are required to clarify this question.
CPA treatment was given for three months, approxi-
mately six months, one and two years in the four relevant
studies. This difference may account for the significant
level of statistical heterogeneity detected in mortality and
the incidence of serious infections. Pulse therapy also
causes significantly more nausea but less leukopenia and
serious infections. In the light of data from Jayne 2003, it
would seem reasonable to suggest that continuous oral
CPA should be limited to three months treatment if the
patient has achieved a sustained remission with a change
to AZA for maintenance therapy. The optimal regimen
for CPA administration for remission induction in ANCA
associated vasculitis remains unclear.
Rituximab vs cyclophosphamide alone for remission 
induction
The RITUXVAS and RAVE studies are two well designed
studies showing that Rituximab is equivalent to CPA
therapy for remission induction whilst side effects occur
at a similar frequency albeit possibly in a smaller number
Figure 6 Forest plot showing the risk ratio of relapse in patients treated with continuous or pulse CPA at 1 and 2 years and at study end. 
Overall continuous treatment with CPA results in a reduced rate of relapse.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Table 5: Inclusion criteria for other remission induction studies
Study ID Inclusion criteria Exclusion criteria
Hu 2008 Newly diagnosed active ANCA associated vasculitis.
Over 18 years of age with renal involvement 
with serum creatinine < 500 uM.
ANCA positive or ANCA negative with confirmatory 
renal Biopsy
Cytotoxic drug treatment in 6 months prior. 
HBV, HCV, HIV or active CMV viral infection, 
acquired immune deficiency, severe renal failure 
with creatinine > 500 uM or on renal replacement 
therapy, life-threatening organ manifestations 
(lung haemorrhage or CNS involvement), active TB, 
liver dysfunction, pregnancy or inadequate 
contraception if female, under age 18 or over 65.
Jones 2008
(RITUXVAS)
A new diagnosis of Wegener's Granulomatosis (WG), 
Microscopic Polyangiitis (MP) or Renal-Limited 
Vasculitis (RLV)
Renal involvement attributable to active WG, MP or 
RLV with at least one of the following:
Biopsy demonstrating necrotizing glomerulonephritis
Red cell casts on urine microscopy or ≥++ haematuria
Anti-Neutrophil Cytoplasmic Antibodies (ANCA) positivity;
ANCA positivity requires either:
Proteinase 3 anti-neutrophil cytoplasmic antibody 
(PR3-ANCA) by Enzyme-Linked Immunosorbent Assay (ELISA) 
or a typical anti-neutrophil cytoplasmic antibody (cANCA) 
pattern by indirect immunofluorescence (IIF), or both 
Myeloperoxidase-anti-neutrophil cytoplasmic antibody 
(MPO-ANCA) by ELISA. A positive peri-nuclear anti-neutrophil 
cytoplasmic antibody (pANCA) by IIF requires 
confirmation by MPO-ANCA ELISA.
1. Previous cyclophosphamide, (greater than 
two weeks of an oral or intravenous [IV] pulse 
cyclophosphamide regimen)
2. Co-existence of another multi-system autoimmune 
disease, e.g. SLE, Churg Strauss syndrome, Henoch 
Schonlein purpura, rheumatoid vasculitis, essential 
mixed cryoglobulinaemia, anti-glomerular basement 
membrane antibody positivity
3. Hepatitis B antigen positive or hepatitis C 
antibody positive
4. Known HIV positive (HIV testing will not 
be a requirement for this trial)
5. Previous malignancy (usually exclude unless 
agreed with trial co-ordinator)
6. Pregnancy, breast feeding or inadequate contraception if 
female
7. Allergy to a study medication
8. Live vaccine within last four weeks
Stone 2009
(RAVE)
Weight of at least 88 lbs (40 kg). Diagnosis of 
Wegener's granulomatosis (WG) or microscopic polyangiitis 
(MPA) according to the definitions of the Chapel Hill 
Consensus Conference. Newly diagnosed patient of WG or 
MPA 
OR must be experiencing a disease flare characterized by: 
(a) active disease with a Birmingham Vasculitis Activity Score
for Wegener's granulomatosis (BVAS/WG) of 3 or greater that 
would normally require treatment with CPA; OR (b) disease 
severe enough to require treatment with CPA; OR (c) must be 
positive for either PR3-ANCA or MPO-ANCA at the screening.
Willing to use acceptable forms of contraception for the
duration of the study and for up to 1 year after stopping 
study medications. Willing to report pregnancies 
(female participants or male participants' partners) 
occurring at any time during the study and for up to 1 
year after stopping study medications.
Parent or guardian willing to provide informed consent, 
if applicable.
Churg-Strauss Syndrome
Limited disease that would not normally be treated with CPA. 
Mechanical ventilation because of alveolar haemorrhage 
History of severe allergic reactions to human or chimeric 
monoclonal antibodies.
Active systemic infection.
Deep-space infection, such as osteomyelitis, septic arthritis, 
or pneumonia complicated by pleural cavity or lung abscess, 
within 6 months prior to study entry.
History of or current hepatitis B or C infection. 
HIV infected. Acute or chronic liver disease.
History of or active cancer diagnosed within the last 5 years.
History of anti-glomerular basement membrane (anti-GBM) 
disease.
Other uncontrolled disease, including drug and alcohol 
abuse.
Pregnancy or breastfeeding.
Jayne 
2000
Prior diagnosis of Wegener's granulomatosis or 
microscopic polyangiitis
ANCA positivity at diagnosis.
Active vasculitis with a requirement for 
further therapy.
At least 2 months treatment with prednisolone and 
cyclophosphamide or azathioprine
Age 18 or over
IVIg in previous 3 months history of 
anaphylaxis to matched blood products
selective IgA deficiency RPGN (20% rise 
in creatinine in 2 weeks) or pulmonary haemorrhage.
Furuta 
1998
Biopsy proven rapidly progressive GN. None Stated
Stegmayr 
1999
RPGN ≥ 50% crescents; included WG, 
Goodpasture's syndrome, MPA
HIV, hepatitis A, B or C virus, severe congestive 
heart failure, malignancy, septicaemia.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Table 6: Interventions in other remission induction studies
Study ID Treatment Control Study outcomes
Hu 2008 MMF 2 G/d (1.5 G if weight < 50 kg) for 6 
months Immunosuppression as for 
control group
Intravenous CPA for 6 months as 0.75-
1.0 G/m2, modified depending on WCC 
nadir Iv MethylPrednisolone 0.5 G daily 
for three days both groups followed by 
oral prednisolone at 0.6-0.8 mg/kg/d for 
4 weeks tapered by 5 mg/wk to 10 mg/d
1. Remission rate at 6 months. Defined as 
no clinical signs of vasculitis, improved 
or stable renal function, no active 
urinary sediment and BVAS score 0.
2. Changes in renal function, side effects
Jones 2008
(RITUXVAS)
Rituximab, 375 mg/m2 IV once a week for 
4 weeks (i.e. 4 doses total), with 2 doses 
of cyclophosphamide 15 mg/kg, 2 
weeks apart given with the 1st and 3rd 
rituximab dose.
All patients received 1 g IV 
methylprednisolone, then same daily 
oral corticosteroid regimen.
CPA 15 mg/kg for 3-6 months (6-10 
doses total)
IV for remission induction. AZA for 
remission maintenance.
All patients received 1 g IV 
methylprednisolone, then same daily 
oral corticosteroid regimen.
1. Primary
i) Sustained remission (BVAS = 0 at 6 
months and sustained for 6 months).
ii) Severe adverse events at 2 years.
2. Secondary
a. Efficacy Response rate at 6 weeks 
(BVAS < 50% baseline) Remission at 6 
months (BVAS = 0 for 2 months by 6 
months) Time to remission (BVAS = 0) 
Relapses (all relapses and major/minor) 
BVAS area under the curve Change in 
GFR Change in SF-36 Change in VDI b. 
Safety Severe adverse events at 6 weeks 
and 6 months. All adverse events. Death. 
Prednisolone cumulative dose. CPA 
cumulative dose 3. Tertiary.
Human anti-chimeric antibody testing 
Correlation of B cells with disease 
activity Change in ANCA and disease 
activity Histopathology predictors of 
outcome.
Stone 2009
(RAVE)
rituximab (375 mg/m2) infusions once 
weekly for 4 weeks and 
cyclophosphamide (CPA) placebo daily 
for 3 to 6 months.
Remission Maintenance: discontinue 
CPA placebo and start oral azathioprine 
(AZA) placebo daily until Month 18
Both groups: Iv MP 1-3 G then 
Prednisolone 1 mg/kg/d reduced to 40 
mg month 1, tapered to discontinue at 
the end of month 6
rituximab placebo infusions once 
weekly for 4 weeks and CPA daily for 3 to 
6 months Remission Maintenance: 
discontinue CPA and start AZA daily 
until Month 18.
Both groups: Iv MP 1-3 G then 
Prednisolone 1 mg/kg/d reduced to 40 
mg month 1, tapered to discontinue at 
the end of month 6
Primary outcome measures
Complete remission during the first 6 
months after randomisation
Secondary outcome measures Adverse 
events
Jayne 2000 IVIg 0.4 G/kg/d for 5 days Placebo (identical injections) Primary outcome: treatment response. 
BVAS reduction of 50% between entry 
and 3 months Secondary outcomes: fall 
in BVAS, CRP and ANCA, relapse 
frequency between 3 and 12 months, 
reduction in immunosuppressive drug 
doses and adverse effect
Furuta 1998 Three 1 hour sessions of 
lymphocytapheresis on alternate days in 
each of three consecutive weeks.
Immunosuppression as for control group
1 G MP iv for 3 consecutive days in each 
of three consecutive weeks.
BOTH GROUPS: Prednisolone 20 mg/day 
and CPA 50 mg/day.
1. SCr 4 weeks post treatment
2. Mortality
Stegmayr 1999 Immunoadsorption: At least 2 plasma 
volumes were removed. Median of 6 
sessions.
Immunosuppression as for control 
group
3 PE in first 5 days of at least 1 plasma 
volume.
4% Albumin as replacement. Median of 
six sessions.
All patients received 
immunosuppression with pulse MP and 
oral or iv CPA 2 mg/kg/day. CPA 
continued for 8 weeks or longer if ANCA 
positive.
1. CrCl and SCr
2. Responder (CrCl improved by at least 
20 ml/min or patient could leave 
dialysis)
3. Adverse events
4. Dialysis
5. DeathWalters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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of patients with rituximab. Given recent papers suggest-
ing that the side effects of cyclophosphamide are more
common than previously thought[42], the threshold for
rituximab use is likely to fall, in spite of its expense.
Mycophenolate for remission induction
The data currently available on this question remain
sparse. The study by Hu et al is encouraging in that it
does not show a reduction in remission induction with
MMF. The next question is the subsequent relapse rate
after MMF use for induction and this has not so far been
addressed. If the relapse rate is particularly high, MMF
may simply turn out to be an expensive prelude to CPA.
The population in this trial is significantly different from
those in other studies, most obviously in the proportion
of patients with MPO-ANCA and microscopic polyangii-
tis at 87%. This is significantly different from that
reported from Europe where the majority of patients are
PR3-ANCA positive. The remission rate is also lower
than that achieved in similar studies from Europe with
only 44% of patients achieving remission as opposed to
over 90% (Jayne 2003). The external validity of the trial
and wider applicability of its results remain to be estab-
lished.
Intravenous immunoglobulin use for refractory vasculitis
The single RCT in this area suggests a short term benefit
lasting up to 3 months. The treatment can be viewed as a
therapy available to help induce remission but has little
bearing on the longer term problem of remission mainte-
nance.
Lymphocytapheresis and immunoadsorption
This novel treatment described by Furuta 1998 gives
some benefit when compared with three weeks of intra-
venous pulse methylprednisolone with a significantly
lower SCr in treated patients. Considering the lack of a
comparison with plasma exchange and the recent data
suggesting the use of plasma exchange is superior to pulse
methylprednisolone, there is currently no compelling rea-
son to consider using this therapy. Immunoadsorption,
similarly, appears to have no benefit over the use of
plasma exchange.
Maintenance Therapy
Azathioprine vs CPA as maintenance therapy
The use of AZA as maintenance therapy after an initial
three month treatment with CPA is strongly supported by
the data from Jayne 2003. The number of relapses on
AZA is similar to CPA with fewer episodes of leukopenia
and similar numbers of infections. As well as the data on
reduced leukopenia, the reduction in total dose of CPA is
presumed to reduce longer term side effects from CP A
such as infertility and neoplasia.
Leflunomide or Methotrexate for maintenance therapy
The single study of Leflunomide suggests that this may be
an appropriate treatment for patients who are intolerant
of Azathioprine. There are problems with interpretation
and extrapolation from this study. The dose of metho-
trexate was increased very slowly. Many commentators
felt this to be an inadequate dose, potentially causing the
higher relapse rate and reflecting poorly the potential of
methotrexate in this area. There were also a high number
of adverse events in the leflunomide arm. The study does
however give some data on the use of Leflunomide and
grounds for its clinical use. Final conclusions are difficult
t o  d r a w .  F u r t h e r  s t u d y  o f  l e f l u n o m i d e  i s  w a r r a n t e d  a s
induction therapy and in comparison to Azathioprine as
maintenance therapy.
Figure 7 Forest plot showing the risk ratio for induction of remission in patients treated with or without rituximab at 6 months and at study 
end. There is no significant difference between the groups.Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Azathioprine vs Methotrexate for maintenance therapy
This study showed that the safety and efficacy profiles of
Methotrexate and AZA are comparable. This data clearly
places methotrexate as a better maintenance agent that
MMF since it gave similar relapse rates to AZA. The dos-
ing regimen for MTX in this study was superior to that in
the Leflunomide/Methotrexate study since the rate of rise
in dose was faster and the final dose higher.
Antibiotics for maintenance of remission
The use of co-trimoxazole to maintain remission was
examined by Stegeman 1996. This showed a benefit in
reducing the risk of relapse but not on other outcomes.
Analysis in the paper by life table analysis showed this
result to be statistically significant. On our analysis using
fixed time analysis, it is not statistically significant (P =
0.12). Relapses detected in the study were mainly respira-
tory in nature but 11/23 patients with a relapse also had
progressive glomerulonephritis.
Etanercept use
The stated aim of the single study into the use of etaner-
cept in systemic vasculitis was to demonstrate that the
relapse rate would be reduced. The study failed to show
this and also suggested an increase in the incidence of
malignancy in treated patients. There is currently no
Table 7: Inclusion Criteria for studies of maintenance treatment
Study ID Inclusion criteria Exclusion criteria
Jayne 2003 Diagnosis of WG, MPA or renal limited vasculitis.
Renal involvement, other threatened loss of function of vital 
organ, or both.
ANCA positivity. ANCA negative patients enrolled with biopsy 
evidence of vasculitis.
Cytotoxic drug in previous year.
Other multi-system autoimmune disease, hepatitis B 
antigenaemia, hepatitis C, HIV infection, cancer, pregnancy.
Age: <18 or > 75 years SCr >500 μmol/L
Stegeman 1996 RPGN on biopsy plus lung disease compatible with WG.
Disease limited to respiratory tract.
Meeting Chapel Hill consensus but not criteria 1
Previous reactions to co-trimoxazole.
GFR < 30 ml/min
Long term treatment with antibiotics
Metzler 2007 18 to 75 years of age.
Diagnosis of generalized WG
Successful induction therapy with prednisolone and CPA.
Bone marrow insufficiency (leukopenia < 4000/μl, Hb < 10 g/
dl, thrombocytopaenia > 100,000/μl) serum creatinine > 1.3 
mg/dl (115 uM), malignancies, hepatitis B or C or HIV 
positivity, pregnancy or breast feeding, inadequate 
contraception, chronic liver disease or alcohol abuse, active 
gastric ulcer, lack of compliance, further coexisting 
autoimmune diseases or treatments interfering with the 
MTX/LEF medication.
WGET 2005 Patients with BVAS/WG score of 3 or more.
Stratified to severe (life-threatening manifestations including 
RPGN, alveolar haemorrhage or neuropathy) or limited (skin, 
joints, sinus or mild renal abnormalities).
At least 2 of 5 modified criteria of the American College of 
Rheumatology for classification of Wegener's 
Granulomatosis.
Either new or established disease
None stated
Pagnoux 2008 Patients over 18 years old. Newly diagnosed Wegener's 
Granulomatosis and Microscopic Polyangiitis. Successful 
remission induction.
use of steroids for more than 1 months prior to CPA therapy, 
co-existence of another systemic disease, cancer (unless in 
remission for more than 3 years), HIV, Hep B or C virus 
infection, contraindication to study drugs, pregnancy, 
absence of contraception in pre-menopausal women, mental 
or physical disabilities abrogating ability to consent. Patients 
not entering remission were not randomised.
Hiemstra 2009
(IMPROVE)
Newly diagnosed patients with WG, MPA or renal-limited 
vasculitis.
ANCA positivity.
Age 18 to 75 years
Any cytotoxic drug within previous year.
Co-existence of another systemic autoimmune disease, e.g. 
SLE. Hepatitis B or Hepatitis C infection HIV positivity.
Failure to achieve remission after 6 months of CPA therapy.
Failure to control progressive disease with induction 
protocol.
Malignancy.
Pregnancy or inadequate contraception.
End stage renal failure unless active extra-renal disease 
requires treatment Inability for informed consentWalters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
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Table 8: Interventions for studies of maintenance treatment
Study ID Treatment Control Study Outcomes
Hiemstra 2009
(IMPROVE)
Mycophenolate mofetil 2 G/d for 42 
months
azathioprine 2 mg/kg/d for 42 months 1. Time to first relapse
2. relapse rate
3. Rate of side-effects and intolerance
4. cumulative doses (AZA, CS, MMF),
5. AUC for BVAS, SF-36 or VDI
6. Evolution of titres of ANCA and
CRP
Pagnoux 2008 All patients received identical 
remission induction therapy. Pulse MP 
15 mg/kg for 3 days. Oral prednisolone 
1 mg/kg/d for 3 weeks, tapered to 12.5 
mg at 6 months. Pulse CPA 0.6 G/m2, 3 
doses at 2 week intervals then every 3 
weeks until remission, 3 further 
consolidation doses at 3 week intervals.
Azathioprine 2 mg/kg/d Maintenance 
therapy continued for 12 months then 
withdrawn over 3 months.
Trimethoprim-sulfamethoxazole 320/
1600 daily recommended for WG 
patients for additional 2 years.
Methotrexate 0.3 mg/kg/week, 
increasing every week by 2.5 mg to 25 
mg/week. Folinic Acid 25 mg or Folic 
Acid 5 mg given 48 hours after 
Methotrexate.
Maintenance therapy continued for 12 
months then withdrawn over 3 
months. Trimethoprim-
sulfamethoxazole 1600/320 daily 
recommended for WG patients for 
additional 2 years.
Primary end point:
1. adverse reaction causing death or
leading to discontinuation of the study 
drug.
Secondary end points:
2. any adverse event,
3. severe adverse event,
4. relapse,
5. relapse free survival,
6. event free survival,
7. quality of life.
WGET 2005 Etanercept 25 mg twice weekly by 
subcutaneous injection 
Immunosuppression as for control 
group.
Twice weekly placebo injection
Severe disease: Cyclophosphamide 2 
mg/kg/d.
Replaced with methotrexate if in 
remission at 3 to 6 months.
Limited disease: Methotrexate 0.25 
mg/kg/week to maximum of 25 mg/
week. 12 months after remission, MTX 
dose cut by 2.5 mg each month.
Prednisolone was given to patients 
with severe and limited disease 
starting at 0.5 to 1.0 mg/kg/d.
Tapered to 0 mg at 6 months if no 
relapse.
Patients in remission with creatinine > 
2 mg/dl received Azathioprine 2 mg/
kg/d, decreased after 12 months in 
remission by 25 mg each month.
1. Sustained remission. BVAS/WG score 
0 for at least 6 months.
2. Number and rate of flares during 
treatment, percentage of patients with 
sustained low level of disease activity 
(BVAS/WG < 3 for at least 6 months), 
percentage of patients with a 
remission, cumulative area under the 
curve for the BVAS/WG, adverse events, 
quality of life.
Metzler 2007 Leflunomide. Loading dose of 100 mg/
d for 3 days, followed by 20 mg/d from 
day 4 to end of week 4. Then increased 
to 30 mg/d thereafter.
Prednisolone as per methotrexate 
group.
Methotrexate: 7.5 mg/week weeks 1 to 
4. 15 mg/week for weeks 5 to 8. 20 mg/
week after week 8.
Prednisolone allowed at a dose of 10 
mg/d or less.
In the absence of disease activity, the 
dose was tapered by 2.5 mg/month to 
5 mg, then by 1 mg/month.
1. Number of major and minor relapses.
2. Disease Extent Index (DEI), BVAS, 
patient self assessment of quality of life 
(SF-36), cANCA titre, ESR, CRP.
Stegeman 1996 Co-trimoxazole 960 mg twice daily Placebo 1. Death
2. Remission
Jayne 2003 CPA 1.5 mg/kg/d from remission.
Switched to AZA 1.5 mg/kg/d 12 
months after study entry.
Immunosuppression as for control 
group.
After remission induction, AZA 2 mg/
kg/d with Prednisolone 10 mg/d.
BOTH GROUPS: Remission induction 
with oral CPA 2 mg/kg/d and 
prednisolone 1 mg/kg/d tapered to 
0.25 mg/kg/d by 12 weeks. From 12 
months both groups received AZA 1.5 
mg/kg/d and prednisolone 7.5 mg/d.
1. Relapse by 18 months
2. Side effects including leucopenia 
and infectionsWalters et al. BMC Nephrology 2010, 11:12
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RCT data on the use of infliximab or other anti-TNF
agents. There is some possibility that alternative agents
may produce significantly different outcomes since their
mechanism of action is distinct from that of etanercept.
At this point in time there is no randomised controlled
trial data supporting their use.
Comparison with other reviews
Two previous reviews have covered some of the subjects
addressed in this review. Bosch 2007 provides a broad
review of the treatment of ANCA associated vasculitis
[43]. This includes patients with localized disease and
those without renal vasculitis. They include a large num-
ber of uncontrolled studies. There was no attempt at
meta-analysis. In the area of severe vasculitis with kidney
involvement, there is a brief summary of the randomised
trial data as included in this review. Their conclusions are
similar to ours. de Groot 2001 is a review of the data
relating to the use of pulse or continuous CPA for induc-
tion of remission of ANCA-associated vasculitis and
includes a meta-analysis of the randomised controlled
trial data [13]. As such, it performs a similar metaanalysis
to ours in this area. There are, however, a number of dif-
ferences. de Groot 2001 has utilised all the data from the
Adu study. We have extracted the data only for patients
without polyarteritis nodosa and with more than 0%
glomerular involvement. This accounts for some of the
differences but not all. de Groot 2001 reports that treat-
ment failure is more likely with continuous treatment
with CPA. There are also some differences in results for
relapse rate. Our results show that continuous treatment
is significantly better at preventing relapse. We have stud-
ied relapse as related to the initial number of patients
whereas de Groot 2001 have recorded relapses as related
to achieved remissions. With the higher treatment failure
figures in the continuous arm, de Groot 2001 does not
show a significant difference in the overall relapse rate.
As stated in the introduction, a version of this review
has previously been published in the Cochrane
Library[19]. This is an updated version containing the lat-
est RCT data in several areas not previously published as
part of this review. Most significant is the new data on
pulse versus continuous cyclophosphamide discussed
above. Also included here for the first time are the data
on MMF, leflunomide, IVIG, rituximab and etanercept.
Authors' Conclusions
Implications for practice
Plasma exchange is effective in patients with severe ARF
secondary to vasculitis. On current data, the use of pulse
CPA results in an increased risk of relapse when com-
pared to continuous use but a reduced total CPA dose.
The use of co-trimoxazole is not supported for preven-
tion of relapse of vasculitis. AZA and MTX are effective
as maintenance therapy once remission has been
achieved. Whilst there is evidence for the use of MMF as
an induction agent, the wider applicability of the single
study is questionable. The use of MMF in remission
maintenance should be third line after failure of other
agents such as AZA and MTX. Etanercept is not recom-
mended for use in vasculitis. Leflunomide may be useful
as maintenance therapy but requires further evaluation.
IVIG is useful but only as a short term measure.
Implications for research
Further research is required to address the use of plasma
exchange in patients with SCr < 500 uM at presentation.
Figure 8 Forest plot of risk ratio for relapse in patients treated with or without co-trimoxazole at 1 and 2 years. There is no statistically signif-
icant difference between the groups.Walters et al. BMC Nephrology 2010, 11:12
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Table 9: Summary of quality measures of included studies
Study ID Randomisation method Allocation 
concealment
Blinding:
 Participants
Blinding: 
Investigators
Blinding: 
Outcome 
assessors
Blinding:
 Data assessors
ITT % 
Follow-up
Adu 1997 Computer generated 
random numbers.
Stratified for renal function
AN o N o N o N o Y e s 1 0 0
Cole 1992 computer-generated 
random numbers after 
informed consent
Stratified by urine volume 
(< 400 ml/24 h), need for 
dialysis and > 50% 
glomeruli sclerosed
B No No Yes No No 97
De Groot 
2009a
computer generated, 
performed centrally by 
permuted blocks of 4, 
stratified by country and 
disease. assigned randomly 
1:1 to treatments.
AN o N o N o Y e sY e s 8 3
Furuta 1998 NS B No No NS NS Yes 100
Jayne 2007 NS B No No NS NS Yes 100
Glockner 
1988
By telephone with 
statistician
BN o N o N S N S N o 8 4
Guillevin 
1997
NS B No No NS NS No 93
Haubitz 1998 Stratified at diagnosis B No No NS NS No 84
Jayne 2007 Centrally, block design.
Stratified by diagnosis
AN S N S N S Y e sY e s 1 0 0
Mauri 1985 NS B No No NS NS Yes 100
Pusey 1991 Stratified for severity 
according to renal function 
by random numbers
BN o N o N S N S N o 9 2
Rifle 1980 NS B No No NS NS No 82
Stegeman 
1996
Stratified by group and 
then randomized
B Yes Yes Yes NS No 99
Stegmayr 
1999
NS B No No NS NS No 83
Hu 2008 Not stated B No No No NS Yes 89
Jayne 2000 Central A Yes Yes Yes NS Yes 100
Metzler 2007 Central A No No No No Yes 96
WGET 2000 Stratified by disease 
severity and by centre
A Yes Yes Yes NS Yes 97
Pagnoux 
2008
Permuted blocks of six A No No No NS Yes 100
Hiemstra 
2009
NS NS No No NS NS Yes NS
RAVE NS NS Yes Yes NS NS NS NS
RITUXVAS Central randomisation Yes No No NS NS Yes 100
Allocation concealment: A - adequate. B - Unclear. NS Not Stated.Walters et al. BMC Nephrology 2010, 11:12
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This investigation is currently under way as part of the
PEXIVAS study run by the European Vasculitis Study
Group. A cost effectiveness analysis is also required for
the use of plasma exchange when compared with methyl-
prednisolone. Clearly there is a large difference between
the two therapies in terms of cost, ease of use and compli-
cations of therapy. As the population of patients evolves
over time and patients with milder disease are treated, it
is highly likely that any cost effectiveness analysis would
suggest that a minor benefit potentially conferred by
plasma exchange would come at too great a cost when
compared with IV methylprednisolone. The need for
dialysis after remission induction treatment with cyclo-
phosphamide requires some clarification. Current studies
suggest that pulse CPA may leave more patients on dialy-
sis unnecessarily.
The use of MMF for remission induction is being
examined in the current MYCYC study by the European
Vasculitis Study group. This is a randomised study com-
paring oral MMF with intravenous cyclophosphamide.
This will give further insight into this area with a popula-
tion of patients which is likely to have a higher proportion
of PR3 ANCA positive patients.
A cost effectiveness analysis is also likely to be required
for rituximab. Initial results suggest that there is no major
benefit in terms of efficacy with rituximab compared with
cyclophosphamide. Cost savings may be evident in avoid-
ance of adverse events but this requires further study.
Appendix
Search methods for identification of studies
Relevant studies were obtained form the following
sources
1. The Cochrane Renal Group's specialised register 
and the Cochrane Central Register of Controlled Tri-
als (CENTRAL) in The Cochrane Library, (Issue 1, 
2008). CENTRAL and the Renal Groups specialised 
register contain the hand searched results of confer-
ence proceedings from general and speciality meet-
ings. This is an ongoing activity across the Cochrane 
Collaboration and is both retrospective and prospec-
tive (Master List 2007, http://apps1.jhsph.edu/
cochrane/masterlist.asp). Therefore we will not spe-
cifically search conference proceedings. Please refer 
to The Cochrane Renal Group's Module in The 
Cochrane Library for the most up-to-date list of con-
ference proceedings (Renal Group 2008).
2. MEDLINE (1966 to July 2009) using the optimally 
sensitive strategy developed for the Cochrane Collab-
oration for the identification of RCTs ([27]) together 
with a search strategy developed with input from the 
Cochrane Renal Group's Trial Search Co-ordinator.
3. EMBASE (1980 to July 2009) using a search strategy 
adapted from that developed for the Cochrane Col-
laboration for the identification of RCTs ([28]) 
together with the a search strategy developed with 
input from the Cochrane Renal Group's Trial Search 
Co-ordinator.
4. Reference lists of nephrology textbooks, review 
articles and relevant studies.
5. Letters seeking information about unpublished or 
incomplete studies to investigators known to be 
involved in previous studies. Letters seeking informa-
tion about unpublished or incomplete studies to 
investigators known to be involved in previous stud-
ies.
Database Search terms
#1 wegener*
#2 (rapid* near progress* near glomerulo-
neph*) or (crescent* near glomeruloneph*)
#3 glomerulonephritis
#4 (antineutrophil near cytoplasmic)
CENTRAL #5 vasculitis
#6 goodpasture
#7 polyarteritis
#8 (acute near glomeruloneph*)
#9 (#1 or #2 or #3 or #4 or #5 or #6 or #7 or #8)
1. exp WEGENER'S GRANULOMATOSIS/
2. exp Antibodies, Antineutrophil Cytoplas-
mic/or exp Vasculitis/or exp Glomerulone-
phritis/or exp Polyarteritis Nodosa/
3. rapidly progressive glomerulonephritis.ti.
4. exp GOODPASTURE SYNDROME/
5. vasculitis.tw. (12821)
6. polyarteritis.tw. (1928)
7. wegener$.tw. (3673)
8. (rapid$ adj25 progress$ adj25 glomerulo-
neph$).ti,ab. (906)
9. or/1-8 (86982)
10. randomized controlled trial.pt. (189812)
11. controlled clinical trial.pt. (66435)
12. randomized controlled trials/(32645)
13. random allocation/(50890)
14. double blind method/(78368)
15. single blind method/(8139)
MEDLINE 16. or/10-15 (321286)
17. animals/not (animals/and human/) 
(2792757)
18. 16 not 17 (304657)
19. clinical trial.pt. (383960)
20. exp clinical trials/(155138)
21.(clinic$ adj25 trial$).ti,ab. (99992)
22. cross-over studies/(14545)
23. (crossover or cross-over or cross over).tw. 
(32414)
24. ((singl$ or doubl$ or trebl$ or tripl$) adj25 
(blind$ or mask$)).ti,ab. (77495)
25. placebos/(23040)Walters et al. BMC Nephrology 2010, 11:12
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26. placebo$.ti,ab. (84360)
27. random$.ti,ab. (285800)
28. research design/(38137)
29. or/19-28 (683077)
30. 29 not 17 (633481)
31. 18 or 30 (643563)
32. 9 and 31 (3934)
1. exp wegener's granulomatosis/or wegener's 
granulomatosis.mp.
2. exp Rapidly progressive glomerulonephri-
tis/or rapidly progressive glomerulonephri-
tis.mp.
3. exp neutrophil cytoplasmic antibody/or 
neutrophil cytoplasmic antibody.mp.
4. exp vasculitis/or vasculitis.mp.
5. exp goodpasture syndrome/or goodpasture 
syndrome.mp.
6. exp polyarteritis nodosa/or polyarteritis 
nodosa.mp.
7. exp acute glomerulonephritis/or acute 
glomerulonephritis.mp.
8. exp proliferative glomerulonephritis/or pro-
liferative glomerulonephritis.mp.
9. exp glomerular basement membrane anti-
body/or glomerular basement membrane 
antibody.mp.
10. exp glomerular basement membrane/or 
glomerular basement membrane.mp.
11. or/1-10
12. exp clinical trial/
13. evidence based medicine/
14. outcomes research/
15. crossover procedure/
EMBASE 16. double blind procedure/
17. single blind procedure/
18. prospective study/
19. exp comparative study/
20. placebo/
21. "evaluation and follow up"/
22. follow up/
23. randomization/
24. or/12-23
25. controlled study/not case control study/
26. or/24-25
27. (clinic$ adj5 trial$).ti,ab.
28. ((singl$ or doubl$ or trebl$ or tripl$) adj 
(blind$ or mask$)).ti,ab.
29. random$.ti,ab.
30. placebo$.ti,ab.
31. or/27-30
32. or/24,31
33. limit 32 to human
34. 11 and 33
Abbreviations
AAV: ANCA associated vasculitis; AKF: acute kidney failure; ANCA: Anti-neutro-
phil cytoplasmic antibody; ARF: acute renal failure; AZA: Azathioprine; BVAS:
Birmingham Vasculitis Activity Score; CI: Confidence interval; CPA: cyclophos-
phamide; GBM: glomerular basement membrane; IVIg: Intravenous Immuno-
globulin; MD: mean difference; MMF: Mycophenolate Mofetil; MPO:
Myeloperoxidase; MTX: Methotrexate; NNH: number needed to harm; NNT:
number needed to treat; PR3: Proteinase 3; RCT: randomised controlled trial;
RPGN: rapidly progressive glomerulonephritis; RR: relative risk; RRT: renal
replacement therapy; SCr: Serum Creatinine; SMD: standardised mean differ-
ence; TNF: Tumour necrosis factor; WG: Wegener's Granulomatosis.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
GW was involved in the design of the study, conducted the literature searches,
obtained and analysed studies and wrote the draft and final versions of the
paper. NW was involved in the design of the study conducted the literature
searches, obtained and analysed studies and edited the draft and final versions
of the paper. JC was involved in the design of the study, adjudication on dis-
agreements in data analysis and editing of draft and final versions of the paper.
All authors have read and approved the final manuscript.
Author Details
1Senior Staff Specialist, The Canberra Hospital, Canberra, Australia. Hon. Senior 
Lecturer, Australian National University Medical School, Canberra, Australia, 
2Managing Editor, Cochrane Renal Group, Centre for Kidney Research, 
Westmead, Australia and 3The Children's Hospital at Westmead, Sydney, 
Australia School of Public Health, University of Sydney, Sydney, Australia
References
1. Savage CO, Harper L, Adu D: Primary systemic vasculitis.  Lancet 1997, 
349:553-558.
2. Seo P, Stone JH: The antineutrophil cytoplasmic antibody-associated 
vasculitides.  Am J Med 2004, 117:39-50.
3. Jennette J, Falk R: Renal and systemic vasculitis.  Comprehensive clinical 
nephrology. Mosby 2nd edition. 2003:341-357.
4. Jennette JC, Falk RJ: New insight into the pathogenesis of vasculitis 
associated with antineutrophil cytoplasmic autoantibodies.  Curr Opin 
Rheumatol 2008, 20:55-60.
5. Bolton WK, Sturgill BC: Methylprednisolone therapy for acute crescentic 
rapidly progressive glomerulonephritis.  Am J Nephrol 1989, 9:368-375.
6. Lockwood CM, Rees AJ, Pearson TA, Evans DJ, Peters DK, Wilson CB: 
Immunosuppression and plasma-exchange in the treatment of 
Goodpasture's syndrome.  Lancet 1976, 1:711-715.
7. Pusey CD, Rees AJ, Evans DJ, Peters DK, Lockwood CM: Plasma exchange 
in focal necrotizing glomerulonephritis without anti-GBM antibodies.  
Kidney Int 1991, 40:757-763.
8. Rondeau E, Levy M, Dosquet P, Ruedin P, Mougenot B, Kanfer A, Sraer JD: 
Plasma exchange and immunosuppression for rapidly progressive 
glomerulonephritis: prognosis and complications.  Nephrol Dial 
Transplant 1989, 4:196-200.
9. Lapraik C, Watts R, Bacon P, Carruthers D, Chakravarty K, D'Cruz D, 
Guillevin L, Harper L, Jayne D, Luqmani R, Mooney J, Scott D: BSR and 
BHPR guidelines for the management of adults with ANCA associated 
vasculitis.  Rheumatology (Oxford) 2007, 46:1615-1616.
10. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser 
T, Hellmich B, Jayne D, Kallenberg CGM, Merkel PA, Raspe H, Salvarani C, 
Scott DGI, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R: 
EULAR recommendations for the management of primary small and 
medium vessel vasculitis.  Ann Rheum Dis 2009, 68:310-317.
11. Menahem S, Hiremagalur B, Mudge D, Toussaint N, Walters G: The CARI 
guidelines. 25 Induction and maintenance therapy in ANCA-associated 
systemic vasculitis.  Nephrology (Carlton) 2008, 13(Suppl 2):S24-36.
12. Jayne D: Challenges in the management of microscopic polyangiitis: 
past, present and future.  Curr Opin Rheumatol 2008, 20:3-9.
Received: 21 September 2009 Accepted: 24 June 2010 
Published: 24 June 2010
This article is available from: http://www.biomedcentral.com/1471-2369/11/12 © 2010 Walters et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. BMC Nephrology 2010, 11:12Walters et al. BMC Nephrology 2010, 11:12
http://www.biomedcentral.com/1471-2369/11/12
Page 23 of 23
13. de Groot K, Adu D, Savage CO: The value of pulse cyclophosphamide in 
ANCA-associated vasculitis: meta-analysis and critical review.  Nephrol 
Dial Transplant 2001, 16:2018-2027.
14. Kerr PG, Chadban SJ, Atkins RC: Is there a role for plasma exchange in 
rapidly progressive glomerulonephritis?  Nephrology 2001, 6:141-143.
15. Levy JB, Winearls CG: Rapidly progressive glomerulonephritis: what 
should be first-line therapy?  Nephron 1994, 67:402-407.
16. Jayne DR, Chapel H, Adu D, Misbah S, O'Donoghue D, Scott D, Lockwood 
CM: Intravenous immunoglobulin for ANCA-associated systemic 
vasculitis with persistent disease activity.  QJM 2000, 93:433-439.
17. Nowack R, Birck R, van der Woude FJ: Mycophenolate mofetil for 
systemic vasculitis and IgA nephropathy.  Lancet 1997, 349:774.
18. Tervaert JW, Stegeman CA, Kallenberg CG: Novel therapies for anti-
neutrophil cytoplasmic antibody-associated vasculitis.  Curr Opin 
Nephrol Hypertens 2001, 10:211-217.
19. Walters G, Willis NS, Craig JC: Interventions for renal vasculitis in adults.  
Cochrane Database Syst Rev 2008:CD003232.
20. de Groot K, Harper L, Jayne DRW, Flores Suarez LF, Gregorini G, Gross WL, 
Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, 
Westman K, Savage COS: Pulse versus daily oral cyclophosphamide for 
induction of remission in antineutrophil cytoplasmic antibody-
associated vasculitis: a randomized trial.  Ann Intern Med 2009, 
150:670-680.
21. Hu W, Liu C, Xie H, Chen H, Liu Z, Li L: Mycophenolate mofetil versus 
cyclophosphamide for inducing remission of ANCA vasculitis with 
moderate renal 26 involvement.  Nephrol Dial Transplant 2008, 
23:1307-1312.
22. Metzler C, Miehle N, Manger K, Iking-Konert C, de Groot K, Hellmich B, 
Gross WL, Reinhold-Keller E: Elevated relapse rate under oral 
methotrexate versus leflunomide for maintenance of remission in 
Wegener's granulomatosis.  Rheumatology (Oxford) 2007, 46:1087-1091.
23. Pagnoux C, Mahr A, Hamidou MA, Boffa J, Ruivard M, Ducroix J, Kyndt X, 
Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal 
X, Vinzio S, Cohen P, Mouthon L, Cordier J, Guillevin L: Azathioprine or 
methotrexate maintenance for ANCA-associated vasculitis.  N Engl J 
Med 2008, 359:2790-2803.
24. Stone J, Merkel P, Seo P, Spiera R, Langford C, Hoffman G, Kallenberg C, 
William St Clair E, Fessler B, Tchao N, Ding L, Webber L, Ikle D, 
Weitzenkamp D, Wu W, Brunetta P, Seismundo L, Fervenza F, Keogh K, 
Kissin E, Mieras K, Monach P, Peikert T, Stegeman C, Ytterberg S, Specks U: 
Rituximab versus cyclophosphamide for induction of remission of 
anca associated vasculitis: a randomized controlled trial (rave) 
[abstract].  American College of Rheumatology Annual Meeting. 
Philadelphia 2009.
25. Jones R, Walsh M, Jayne D, for the European Vasculitis Study Group: 
Randomised trial of rituximab versus cyclophophamide for anca 
associated renal vasculitis: rituxvas [abstract].  Annual Scientific Meeting 
of the American Society of Nephrology 2008.
26. The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: 
Etanercept plus standard therapy for Wegener's granulomatosis.  N 
Engl J Med 2005, 352:351-361.
27. Dickersin K, Scherer R, Lefebvre C: Identifying relevant studies for 
systematic reviews.  BMJ 1994, 309:1286-1291.
28. Lefebvre C, McDonald S: Development of a Sensitive Search Strategy for 
Reports of Randomized Controlled Trials in EMBASE.  Fourth 
International Cochrane Colloquium; Adelaide 1996.
29. Cole E, Cattran D, Magil A, Greenwood C, Churchill D, Sutton D, Clark W, 
Morrin P, Posen G, Bernstein K: A prospective randomized trial of plasma 
exchange as additive therapy in idiopathic crescentic 
glomerulonephritis. The Canadian Apheresis Study Group.  Am J Kidney 
Dis 1992, 20:261-269.
30. Glöckner WM, Sieberth HG, Wichmann HE, Backes E, Bambauer R, Boesken 
WH, Bohle A, Daul A, Graben N, Keller F: Plasma exchange and 
immunosuppression in rapidly progressive glomerulonephritis: a 
controlled, multi-center study.  Clin Nephrol 1988, 29:1-8.
31. Jayne DRW, Gaskin G, Rasmussen N, Abramowicz D, Ferrario F, Guillevin L, 
Mirapeix E, Savage COS, Sinico RA, Stegeman CA, Westman KW, van der 
Woude FJ, de Lind van Wijngaarden RAF, Pusey CD: Randomized trial of 
plasma exchange or high-dosage methylprednisolone as adjunctive 
therapy for severe renal vasculitis.  J Am Soc Nephrol 2007, 18:2180-2188.
32. Mauri J, Gonzalez M, Poveda R: Therapeutic plasma exchange in the 
treatment of rapidly progressive glomerulonphritis.  Plasma therapy 
and transfusion technology 1985, 6:587-591.
33. Rifle G, Chalopin JM, Zech P, Deteix P, Ducret F, Vialtel P, Cordonnier D: 
Treatment of idiopathic acute crescentic glomerulonephritis by 
immunodepression and plasma-exchanges. A prospective randomised 
study.  Proc Eur Dial Transplant Assoc 1981, 18:493-502.
34. Adu D, Pall A, Luqmani RA, Richards NT, Howie AJ, Emery P, Michael J, 
Savage CO, Bacon PA: Controlled trial of pulse versus continuous 
prednisolone and cyclophosphamide in the treatment of systemic 
vasculitis.  QJM 1997, 90:401-409.
35. Guillevin L, Cordier JF, Lhote F, Cohen P, Jarrousse B, Royer I, Lesavre P, 
Jacquot C, Bindi P, Bielefeld P, Desson JF, Détrée F, Dubois A, Hachulla E, 
Hoen B, Jacomy D, Seigneuric C, Lauque D, Stern M, Longy-Boursier M: A 
prospective, multicenter, randomized trial comparing steroids and 
pulse cyclophosphamide versus steroids and oral cyclophosphamide 
in the treatment of generalized Wegener's granulomatosis.  Arthritis 
Rheum 1997, 40:2187-2198.
36. Haubitz M, Schellong S, Göbel U, Schurek HJ, Schaumann D, Koch KM, 
Brunkhorst R: Intravenous pulse administration of cyclophosphamide 
versus daily oral treatment in patients with antineutrophil cytoplasmic 
antibody-associated vasculitis and renal involvement: a prospective, 
randomized study.  Arthritis Rheum 1998, 41:1835-1844.
37. Furuta T, Hotta O, Yusa N, Horigome I, Chiba S, Taguma Y: 
Lymphocytapheresis to treat rapidly progressive glomerulonephritis: a 
randomised comparison with steroid-pulse treatment.  Lancet 1998, 
352:203-204.
38. Stegmayr BG, Almroth G, Berlin G, Fehrman I, Kurkus J, Norda R, Olander R, 
Sterner G, Thysell H, Wikström B, Wirén JE: Plasma exchange or 
immunoadsorption in patients with rapidly progressive crescentic 
glomerulonephritis. A Swedish multi-center study.  Int J Artif Organs 
1999, 22:81-87.
39. Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JWC, Dadoniené J, 
Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix 
E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C: A 
randomized trial of maintenance therapy for vasculitis associated with 
antineutrophil cytoplasmic autoantibodies.  N Engl J Med 2003, 
349:36-44.
40. Hiemstra T, Walsh M, Schmitt W, Jayne D: Randomised controlled trial of 
mycophenolate mofetil versus azathioprine for maintenance therapy 
in anca associated vasculitis (improve) [abstract].  Annual Scientific 
Meeting of the American Society of Nephrology 2009.
41. Stegeman CA, Tervaert JW, de Jong PE, Kallenberg CG: Trimethoprim-
sulfamethoxazole (co-trimoxazole) for the prevention of relapses of 
Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study 
Group.  N Engl J Med 1996, 335:16-20.
42. Rüth E, Kemper MJ, Leumann EP, Laube GF, Neuhaus TJ: Children with 
steroid-sensitive nephrotic syndrome come of age: long-term 
outcome.  J Pediatr 2005, 147:202-207.
43. Bosch X, Guilabert A, Espinosa G, Mirapeix E: Treatment of antineutrophil 
cytoplasmic antibody associated vasculitis: a systematic review.  JAMA 
2007, 298:655-669.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2369/11/12/prepub
doi: 10.1186/1471-2369-11-12
Cite this article as: Walters et al., Interventions for renal vasculitis in adults. A 
systematic review BMC Nephrology 2010, 11:12